Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies

Overview

Clinical trial to analyze the impact of nutrition and physical exercise intervention program on the completion of treatment in older patients 70 years or older with malignant hemopathology

Full Title of Study: “Impact of a Nutritional and Physical Exercise Intervention Program on Oncological Treatment Completion in Patients ≥70 Years Old With Malignant Hemopathies:ICOSENIORHEM Randomized Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 1, 2021

Detailed Description

OBJECTIVE: This study aims to determine wether a geriatric intervention based on an individualized program of physical exercise and nutritional support improves the ability to complete oncological treatment at the doses and time initially planned in patients ≥ 70 years affected by hematological malignancies. DESIGN: Prospective, clinical trial, randomized, parallel and open groups. SETTING: Patients ≥ 70 years recently diagnosed of malignant hematological pathology in a comprehensive cancer center INTERVENTION: All those patients who meet the inclusion criteria and agree to participate, will sign the corresponding informed consent and will be assessed through a CGA (comprehensive geriatric assessment), that includes the performance of a physical condition test (SPPB), and randomized to the study group or control group. Patients in the study group will participate in an intervention program with nutritional support and physical exercise during the period in which they are receiving oncological treatment or for a maximum period of 6 months. The patients of the control group will pass to follow up. All patients, regardless of the branch of study to which they are assigned, will receive the oncological treatment indicated by their doctor and a standard follow-up according to the current care protocols in the center. DETERMINATIONS: Main variable: proportion of adherence to treatment calculated as the percentage between the dose administered and the prescribed. Adherence over 80% will be considered acceptable. Secondary variables: geriatric, nutritional and physical-condition parameters before and after the intervention, quality of life before and after the intervention, toxicity and complications during treatment and response to treatment.

Interventions

  • Other: Nutritional support
    • Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
  • Other: Physical exercise
    • The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
  • Drug: Hematologic Drug
    • The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.

Arms, Groups and Cohorts

  • Experimental: Intervention group
    • Patients in the intervention group will follow the standard treatment and follow-uo according to the clinical protocol of the institution and will participate in an intervention program with physical exercise and nutritional support during the period in which they are receiving oncological treatment or for a maximum period of 6 months.
  • Active Comparator: Control group
    • The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.

Clinical Trial Outcome Measures

Primary Measures

  • Adherence to oncological treatment
    • Time Frame: Change from baseline and after finishing treatment or 6 months
    • Percentage between the dose administered and the prescribed.

Secondary Measures

  • Risk of vulnerability
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Vulnerable Elders Survey (VES-13) (numeric variable)
  • Geriatric assessment
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Geriatric Assessment in Hematology (GAH scale) (numeric variable)
  • Nutritional screening
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Mini-Nutritional Assessment (MNA) (numeric variable)
  • Functional capacity
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Basic activities of daily life (ABVD) – (Barthel scale) and instrumental activities of daily life (IADL) (Lawton-Body scale), fatigue (Borg scale) (numeric variable)
  • Physical condition screening
    • Time Frame: Change from baseline versus 6 months (end of intervention) versus 12 months
    • Short Portable Physical Performance (SPPB) test. Numeric variable.
  • Physical condition tests
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Walking test 4 metres, Up-and-go test (seconds)
  • Body mass index
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Weight and height will be combined to report body mass index (BMI) in kg/m2
  • Anthropometric evaluation
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Anthropometric evaluation of waist, hip, arm, thigh and leg perimeters (cm).
  • Body composition
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Body mass measured with electrical bioimpedance
  • Performance of muscular strength
    • Time Frame: Baseline versus 6 months (end of intervention) versus 12 months
    • Strength measured by Isometric dynamometry of hands (hand grip) and legs (flex-extension) (KgF)
  • Functional capacity assessment
    • Time Frame: Change from baseline versus 6 months (end of intervention) versus 12 months
    • 6-minute walk test to assess functional capacity.
  • Assessment of lower limbs strengh
    • Time Frame: Change from baseline versus 6 months (end of intervention) versus 12 months
    • Test to sit and get up in 30 seconds
  • Average number of exercise sessions completed
    • Time Frame: Through study completion, an average of 6 months
    • Number of exercise sessions completed by each participant in the intervention group.
  • Incidence of adverse effects
    • Time Frame: Through study completion, an average of 6 months
    • Frequency and severity of adverse effects according to CTCAE v4.
  • Quality of life Assessment
    • Time Frame: Change from baseline versus 6 months (end of intervention) versus 12 months
    • Quality of Life Assessment: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ)for old patients with cancer. (EORTC QLQ-ELD14): numeric variable.
  • Disease progression
    • Time Frame: Change from baseline and after 2 years
    • Time to treatment failure, time to disease progression or death from any cause, and time to disease progression
  • Survival
    • Time Frame: Change from baseline and after 2 years
    • Disease-free survival, overall survival, and cancer-specific survival.

Participating in This Clinical Trial

Inclusion Criteria

  • hematological pathology (myelodysplastic syndromes, lymphoproliferative syndromes, multiple myeloma) – considered able to practice physical exercise – signed informed consent Exclusion Criteria:

  • other hematological pathology – considered unable to practice physical exercise

Gender Eligibility: All

Minimum Age: 70 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Maite Antonio, MD, Phd
  • Collaborator
    • Institut d’Investigació Biomèdica de Bellvitge
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Maite Antonio, MD, Phd, Coordinator Oncohematogeriatrics Unit. Institut Català d’Oncologia – L’Hospitalet de Llobregat
  • Overall Official(s)
    • Maite Antonio, MD,PhD, Principal Investigator, Institut Català d’Oncologia
  • Overall Contact(s)
    • Maite Antonio, MD, PhD, +34692083987, marebollo@iconcologia.net

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.